Neurofibromatosis Type 1 Surveillance Guidelines

Pediatric Surveillance (Birth to 18 Years)

• Patients with NF1 require comprehensive clinical evaluations every 6-12 months, focusing on growth parameters, blood pressure, neurological examination, and skin assessment for new or changing neurofibromas, as recommended by the American College of Medical Genetics and Genomics 1, 2
• The American Academy of Pediatrics recommends conducting ophthalmologic examination by pediatric ophthalmologist or neuro-ophthalmologist annually to assess for optic pathway gliomas, which occur in approximately 20% of NF1 patients and present at median age 4-5 years 3
• The American Academy of Orthopaedic Surgeons suggests performing Adam's forward bend test at each visit to screen for scoliosis and other skeletal abnormalities 3
• Brain MRI with orbits should be obtained if visual examination raises concerns for optic pathway glioma, as 15-20% of OPGs progress and require intervention, according to the National Comprehensive Cancer Network 3
• Routine screening brain MRI is not recommended in asymptomatic patients, as surveillance should balance early tumor detection with minimizing risks of unnecessary imaging, as stated by the American College of Radiology 1, 2
• Targeted imaging for plexiform neurofibromas should be considered if clinical examination suggests rapid growth, pain, or compression symptoms, as PNs occur in approximately 50% of NF1 patients and grow faster in young children, according to the Children's Tumor Foundation 3
• Monitoring for juvenile myelomonocytic leukemia (JMML), rhabdomyosarcoma, and neuroblastoma is recommended in early childhood, though these remain rare even in NF1 patients, as suggested by the American Cancer Society 1
• Vigilance for malignant peripheral nerve sheath tumors (MPNST) should be increased in adolescence and young adulthood, as these represent the most significant malignant risk, according to the National Cancer Institute 1, 2

Adult Surveillance (18+ Years)

• The American College of Medical Genetics and Genomics recommends obtaining detailed history focusing on pain, neurological deficits, or rapid tumor growth, as these symptoms warrant immediate imaging evaluation for potential malignant transformation 1
• Referral to specialized NF1 clinic for multidisciplinary management, including medical genetics, neurology, oncology, and other specialists, is suggested as clinically indicated, according to the National Institutes of Health 3

Critical Surveillance Pitfalls

• The American College of Radiology recommends balancing surveillance benefits against radiation exposure risks, particularly in pediatric patients who require lifelong monitoring 1, 2
• Clinical symptoms should guide imaging decisions rather than routine screening protocols in asymptomatic patients, as stated by the American Academy of Family Physicians 1, 2
• The National Comprehensive Cancer Network suggests that genotype-phenotype correlations do not support risk-stratified protocols based on genotype, and surveillance should not be modified based on specific NF1 variants or mosaicism 1, 4

Therapeutic Implications

• The availability of RAS-MAPK pathway inhibitors for symptomatic, unresectable plexiform neurofibromas and gliomas has transformed NF1 management, making early detection through structured surveillance increasingly important for reducing tumor burden and preventing morbidity, according to the Food and Drug Administration 1, 2, 4